Novartis | NVS - Ordinary Share Capital


Novartis reported $1.91B in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Amgen USD 540M 1000K Mar/2026
AstraZeneca USD 1.55B 44K Jun/2026
Bausch Health Companies USD 373.9M 436K Jun/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Canopy Growth CAD 422.07M 53.78M Mar/2026
Corcept Therapeutics USD 107.33M 1.36M Mar/2026
Drreddys Laboratories INR 832.69M 123K Mar/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
J&J USD 2.41B 1.35M Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Novartis USD 1.91B 60K Mar/2026
Pacira USD 39.31M 1.81M Mar/2026
Perrigo USD 138.1M 500K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Phibro Animal Health USD 40.48M 0 Dec/2025
Prestige Brands USD 47.32M 765K Dec/2025
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Sanofi EUR 1.2B 16.88M Mar/2026
Supernus Pharmaceuticals USD 58.16M 124K Jun/2026
Zoetis USD 420.35M 4.58M Mar/2026